Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202608036 A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis
TMUH / I-Wen Wu
New Drug Phase Ⅱ
N202608038 A Randomized, Open-label, Phase 3 Trial of Petosemtamab + FOLFIRI/mFOLFOX6 Versus Cetuximab or Bevacizumab + FOLFIRI/mFOLFOX6 as Second-line Treatment in Participants With RAS and BRAF Wild-type, Recurrent, Unresectable or Metastatic Colorectal Cancer New Drug Phase Ⅲ
N202608042 Feasibility assessment of constructing a continuous glucose monitoring system using electrocardiogram data New Medical Device NA
N202608045 A randomized, open-label (unblinding), four-period, fully-replicated, crossover bioequivalence study to compare two edoxaban tosilate F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202608056 An Open-Label, Randomized, and Crossover Bioequivalence Study of Dapagliflozin 10 mg Film-Coated Tablet in Healthy Subjects under Fasting Conditions New Drug Phase Ⅰ
N202608057 A randomized, open-label (unblinding), crossover bioequivalence study to compare two empagliflozin F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202608058 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PYC-003, a Peptide-Phosphorodiamidate Morpholino Oligonucleotide Conjugate, in Healthy Adult Participants and Adult Participants with Confirmed PKD1 Mutation Associated Autosomal Dominant Polycystic Kidney Disease New Drug Phase Ⅰ
N202608059 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF REGN7508, A MONOCLONAL ANTIBODY AGAINST FXI, FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) New Drug Phase Ⅲ
N202608075 A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared with Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease (Stage 3b and 4) New Drug Phase Ⅲ
1 2 23 24 25 26 27 28 29 30 31 32 / 32

TOP